The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.

According to one embodiment, a composition is for delivering an objective substance to the T-cell malignant tumor cell. The composition contains a substance delivery carrier. The substance delivery carrier has a lipid particle, and the objective substance encapsulated in the lipid particle. The lipid particle contains, as constituents thereof, at least a first lipid represented by formula (I) and a second lipid represented by formula (II).

Materials and methods for preparing a payload-containing microcapsule with walls that have hexahydrotriazine (HT) and/or hemiaminal (HA) structures are disclosed. To an HT small molecule or a HA small molecule, or a combination thereof, in a solvent is added a cross-linking agent, NH.sub.4Cl, and a copolymer. The solution is acidified, and a payload agent is added. The HT small molecule and HA small molecule may have orthogonal functionality.

The present invention relates to a buccal delivery dosage form and its use for administration of a therapeutic gas for buccal mucosal absorption of the therapeutic gas in the mouth of a subject. The buccal delivery dosage form comprises at least one crystallized excipient and at least one therapeutic gas entrapped within the crystalized excipient.

The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.

Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.

The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.

##STR00001##

The present invention is directed to particle comprising a supramolecular complex comprising a monofunctional and/or a bifunctional subunit comprising a quadruple hydrogen bonding unit, an apolar linker, an urea group, and a polyethyleneglycol linker. The monofunctional subunits comprise a functional group. The particles are very suitable as drug delivery system as they bind and enter the cell and may have slow release properties.

An object is to provide a formulation that includes a particle containing an active ingredient and a surfactant, and a base, and is more excellent in storage stability. For solution, a formulation including a particle containing an active ingredient and a surfactant, and a base, in which the surfactant is contained in a ratio of 5 to 100 parts by weight based on 1 part by weight of the active ingredient, is provided.

Synthetic liposomal nanoparticles comprising a cell-free transcription and translation machinery, a plasmid encoding a cytokine, and a regulatable caged ATP molecule, as well as microparticles encasing the synthetic liposomal nanoparticles and methods of making and using the synthetic liposomal nanoparticles, are described herein. These liposomal nanoparticles may be used for the controlled release o a cytokine within a localized environment of, for example a tumor, as part of a therapeutic treatment of cancer, or for localized treatment at a focus of interest of an autoimmune disease, an allergic reaction or hypersensitivity reaction, a localized site of an infection or infectious disease, a localized site of an injury or other damage, a transplant or other surgical site, or a blood clot. Further, microparticles produced by encapsulating hundreds of liposomal nanoparticles, and their therapeutic uses, are also described.